Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world AML study to track treatment outcomes over 10 years

NCT ID NCT04777916

Knowledge-focused Sponsor: Acute Leukemia French Association Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 5,000 adults with acute myeloid leukemia (AML) in French hospitals to see how they are actually treated and how they fare over time. Researchers will collect data on treatments, survival, and disease progression for up to 10 years. The goal is to understand real-world care outside of clinical trials, which may help improve future treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could reveal which AML treatments work best in everyday practice, helping doctors make more informed decisions.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

Apr 2046

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Natural History and assessment of the outcomes of different standard approved treatments in recently diagnosed or relapsed/refractory AML patients

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged 18 years old or more * Patient with newly diagnosed previously untreated de novo, secondary or therapy-related AML * Patients with R/R de novo, secondary or therapy-related AML * Patient with Health insurance Exclusion Criteria: * Acute promyelocytic leukemia * AML which is not morphologically proven (patients with granulocytic sarcoma may be included) * For newly diagnosed AML: previous treatment of leukemia apart from hydroxyurea. Previous anti leukemia treatments are allowed if they were administered before the diagnosis of AML to treat a MDS, MPN, MPN/MDS or CML * Patient weighting less than 50 kgs * Opposition of the patient to participate to this non-interventional study More specific eligibility criteria might be requested to enter some study modules

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myeloid leukemia (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myeloid leukemia (AML)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HP-GHU - Hôpital AVICENNE

    RECRUITING

    Bobigny, France

  • C H U DE LIMOGES- Hopital Dupuytren

    RECRUITING

    Limoges, France

  • CHRU de Lille- Hopital C. HURIEZ

    RECRUITING

    Lille, France

  • CHU Dijon- François Mitterrand

    ACTIVE_NOT_RECRUITING

    Dijon, 21000, France

  • CHU La Conception

    RECRUITING

    Marseille, France

  • CHU Nice,Hopital Archet 1

    RECRUITING

    Nice, France

  • CHU de la cote de Nacre

    RECRUITING

    Caen, France

  • Centre Antoine Lacassagne

    RECRUITING

    Nice, France

  • Centre Henri Becquerel

    RECRUITING

    Rouen, France

  • Centre Hopsitalier de l'Est Francilien - Site de Meaux

    RECRUITING

    Meaux, France

  • Centre Hospitalier Dr Schaffner

    RECRUITING

    Lens, France

  • Centre Hospitalier Lyon Sud

    RECRUITING

    Pierre-Bénite, France

  • Centre Hospitalier René Dubos

    RECRUITING

    Pontoise, France

  • Centre Hospitalier Valenciennes

    NOT_YET_RECRUITING

    Valenciennes, France

  • Centre Hospitalier Victor Dupouy

    RECRUITING

    Argenteuil, France

  • Centre Hospitalier de Dunkerque

    RECRUITING

    Dunkirk, France

  • Centre Hospitalier de Roubaix

    RECRUITING

    Roubaix, France

  • Centre Hospitalier de St Quentin

    RECRUITING

    Saint-Quentin, France

  • Centre Hospitalier de Versailles André Mignot

    RECRUITING

    Le Chesnay, France

  • Centre hospitalier Sud Francilien

    RECRUITING

    Corbeil-Essonnes, France

  • Chu Amiens

    RECRUITING

    Amiens, France

  • GHICL-Hopital St Vincent de Paul

    RECRUITING

    Lille, France

  • Hopital Pitié-Salpétrière APHP

    RECRUITING

    Paris, France

  • Hôpital Henri Mondor AP-HP

    RECRUITING

    Créteil, France

  • Hôpital MILITAIRE PERCY

    RECRUITING

    Clamart, France

  • Hôpital Necker - APHP

    RECRUITING

    Paris, France

  • Hôpital SAINT ANTOINE-APHP

    RECRUITING

    Paris, France

  • Hôpital Saint Louis- APHP

    RECRUITING

    Paris, France

  • Institut Curie - Hôpital René HUGUENIN

    NOT_YET_RECRUITING

    Saint-Cloud, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.